Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258511 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT07258511: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
NCT07258511 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 400 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07258511, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Primary Outcome
Overall response is defined as having achieved partial response (PR) or better, according to the international myeloma working group (IMWG) response criteria, as assessed any time after first administration of study treatment, but prior to progression of disease (PD) or subsequent antimyeloma therapy.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG JNJ-79635322
Study Locations (20)
Other
- Box Hill Hospital - Box Hill
- Mater Misericordiae Ltd - Brisbane
- St Vincents Hospital Melbourne - Fitzroy
- The Alfred Hospital - Melbourne
- Gold Coast University Hospital - Southport
- Hospital De Clinicas De Porto Alegre - Porto Alegre
- Soroka Medical Center - Beersheba
- Bnai Zion Medical Center - Haifa
New York
- Mount Sinai Chelsea - New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Connecticut
- University of Connecticut Health Center - Farmington
- Yale Cancer Center - New Haven
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Florida
- Florida Cancer Specialists & Research Institute - Fort Myers
Georgia
- Emory University - Atlanta
Kentucky
- Norton Cancer Institute - Louisville
North Carolina
- Durham VAMC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-02-04 |
| Est. Completion | 2031-09-30 |
| Phase | Phase 3 |
What NCT07258511 shows while recruiting
NCT07258511 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.
NCT07258511 names 20 study sites across 10 states, led by Other, New York, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07258511 about?
NCT07258511 is a clinical study titled "A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
What is the current status of trial NCT07258511?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2026-02-04. Estimated completion is 2031-09-30.
What conditions does trial NCT07258511 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT07258511?
The interventions under investigation include: Teclistamab (DRUG), JNJ-79635322 (DRUG).
Who is sponsoring clinical trial NCT07258511?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07258511 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07258511's enrollment target sits among peer trials
400 58th of 438 higher than 381 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI